If you have been reading about insulin-like growth factor 1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Bulalô (Tagalog: [bʊ.lɐˈlɔʔ]) is a beef dish from the Philippines. It is made by slow-cooking beef shanks and bone marrow until the collagen and fat has melted into a light-colored broth. It typically includes leafy vegetables (for example pechay or cabbage), corn on the cob, scallions, onions, garlic, ginger, and fish sauce. Potatoes, carrots, or taro may be added. It is commonly eaten with rice, with soy sauce and calamansi on the side. Bulalo is native to the Southern Luzon region of the Philippines, particularly in the provinces of Batangas and Cavite. Bulalo is a pre-colonial Filipino dish. Its name comes from the word bulalo, which means "bone marrow" in Tagalog (also extending to mean "kneecap"). Bulalo originally does not include vegetables or starchy ingredients (aside from the flavoring ingredients and spices). Though in modern times, vegetables have become more typical in most bulalo recipes. The key distinguishing ingredient of the dish is the bone marrow, which differentiates it from similar beef broth dishes in the Philippines. Bulalo is most commonly confused with nilagang baka, since both can share almost all of the same ingredients. However, nilagang baka only uses meaty and fatty cuts of beef and does not include bone marrow. Other similar dishes in other parts of the Philippines (which may or may not include bone marrow) include the Western Visayan cansi which is soured with batuan fruit; the Waray dish pakdol; and the Cebuano dish pochero.
Feduccia's frill argument was followed up in several other publications, in which researchers interpreted the filamentous impressions around Sinosauropteryx fossils as remains of collagen fibres rather than primitive feathers. Since the structures are clearly external to the body, these researchers have proposed that the fibres formed a frill on the back of the animal and underside of its tail, similar to some modern aquatic lizards. The absence of feathers would refute the proposal that Sinosauropteryx is the most basal known theropod genus with feathers, and also raise questions about the current theory of feather origins itself. It calls into question the idea that the first feathers evolved not for flight but for insulation, and that they made their first appearance in relatively basal dinosaur lineages that later evolved into modern birds. Most researchers have disagreed with the identification of the structures as collagen or other structural fibres. Notably, the team of scientists that reported the presence of pigmentation cells in the structures argued that their presence proved the structures were feathers, not collagen, because collagen does not contain pigment. Gregory S. Paul reidentified what the collagen hypothesis's proponents consider a body outline outside of the fibres as an artefact of preparation: breakage and brushed-on sealant have been misidentified as the outline of the body. The hypothesis that the structures were collagen fibers was closely analyzed and disproven by a 2017 paper published by Smithwick et al.
Derek Malcolm of the Evening Standard felt that the movie was a "dim reworking of Fatal Attraction" and noted: "Larter as the pathological minx is the best thing about it." Obsessed opened No. 1 in its opening weekend with $28 million, and making a total domestic gross of $68 million, becoming Larter's second highest-grossing film in North-America. Larter was nominated for a third time for a Teen Choice Award when she and Beyoncé were nominated for the Teen Choice Award for Choice Movie: Rumble at the 2009 Teen Choice Awards and an MTV Movie Award for Best Fight both for Obsessed. Larter reprised her role of Claire Redfield in Resident Evil: Afterlife (2010), which was filmed in 3D and saw her character ambushed and mentally manipulated by the fictional Umbrella Corporation, before she is rescued by Alice (Milla Jovovich). Like the previous Resident Evil entries, the film received negative reviews but became a major commercial success, earning $296 million worldwide. On returning to the role of Claire, Larter told JoBlo.com: "I guess people liked me as her... I'm excited that they brought me back... to work with the man [Paul W. S. Anderson] who really created this world and this vision was what excited me about joining this next installment". In 2010, Larter appeared as the title character in a short film for Absolut Vodka entitled "Lemon Drop". After the release of Afterlife, Larter went on hiatus to focus on her family.
=== Use in radioisotope thermoelectric generators === Beginning on January 1, 1957, Mound Laboratories RTG inventors Jordan & Birden were working on an Army Signal Corps contract (R-65-8- 998 11-SC-03-91) to conduct research on radioactive materials and thermocouples suitable for the direct conversion of heat to electrical energy using polonium-210 as the heat source. In 1961, Capt. R. T. Carpenter had chosen 238Pu as the fuel for the first RTG (radioisotope thermoelectric generator) to be launched into space as auxiliary power for the Transit IV Navy navigational satellite. By January 21, 1963, the decision had yet to be made as to what isotope would be used to fuel the large RTGs for NASA programs. Early in 1964, Mound Laboratories scientists developed a different method of fabricating the weapon component that resulted in a production efficiency of around 98%. This made available the excess Savannah River 238Pu production for Space Electric Power use just in time to meet the needs of the SNAP-27 RTG on the Moon, the Pioneer spacecraft, the Viking Mars landers, more Transit Navy navigation satellites (precursor to today's GPS) and two Voyager spacecraft, for which all of the 238Pu heat sources were fabricated at Mound Laboratories. The radioisotope heater units were used in space exploration beginning with the Apollo Radioisotope Heaters (ALRH) warming the Seismic Experiment placed on the Moon by the Apollo 11 mission and on several Moon and Mars rovers, to the 129 LWRHUs warming the experiments on the Galileo spacecraft.
Sources: en.wikipedia.org
=== Naval warfare capabilities === In course of the Yemeni Civil War, the Houthis developed tactics to combat their opponents' navies. At first, their anti-ship operations were unsophisticated and limited to rocket-propelled grenades being shot at vessels close to the shore. In the fight to secure the port city of Aden in 2015, the Yemeni Navy was largely destroyed, including all missile-carrying vessels. A number of smaller patrol craft, landing craft, and Mi-14 and Ka-28 ASW helicopters did survive. Their existence under Houthi control would be brief, as the majority of them were destroyed in air attacks during the Saudi-led intervention in Yemen in 2015. As a result, the Houthis were left with AShMs (anti-ship missiles) stored ashore, but no launchers, and a smattering of small patrol ships. These, along with a number of locally manufactured small craft and miscellaneous vessels, were to form the foundation of the new naval warfare capabilities. Soon after the Houthis took over Yemen in 2015, Iran sought to strengthen the Houthis' naval capabilities, allowing the Houthis, and thus Iran, to intercept Coalition shipping off the Red Sea coast, by providing additional AShMs and constructing truck-based launchers that could easily be hidden after a launch. Iran also anchored the MV Saviz intelligence vessel, disguised as a regular cargo vessel, off the coast of Eritrea, that provided intelligence and updates on Coalition ship movements to the Houthis.
==== Inhibition ==== Factors from the lining of vessels stop platelets from activating. An intact endothelial lining inhibits platelet activation by producing nitric oxide, endothelial-ADPase, and PGI2 (prostacyclin). Endothelial-ADPase degrades the platelet activator ADP. Resting platelets maintain active calcium efflux via a cyclic AMP-activated calcium pump. Intracellular calcium concentration determines platelet activation status, as it is the second messenger that drives platelet conformational change and degranulation. Endothelial prostacyclin binds to prostanoid receptors on the surface of resting platelets. This event stimulates the coupled Gs protein to increase adenylate cyclase activity and increases the production of cAMP, further promoting the efflux of calcium and reducing intracellular calcium availability for platelet activation. ADP binds to purinergic receptors on the platelet surface. Since the thrombocytic purinergic receptor P2Y12 is coupled to Gi proteins, ADP reduces platelet adenylate cyclase activity and cAMP production, leading to accumulation of calcium inside the platelet by inactivating the cAMP calcium efflux pump. The other ADP-receptor P2Y1 couples to Gq that activates phospholipase C-beta 2 (PLCB2), resulting in inositol 1,4,5-trisphosphate (IP3) generation and intracellular release of more calcium. This together induces platelet activation. Endothelial ADPase degrades ADP and prevents this from happening. Clopidogrel and related antiplatelet medications also work as purinergic receptor P2Y12 antagonists.
== Preparation == The bombe mold is lined with ice cream and filled with a mixture that called pâte à bombe so the ice cream forms the outer shell of the dessert. The filling can be flavored with a fruit-based coulis like raspberry.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.